R
René Adam
Researcher at Université Paris-Saclay
Publications - 634
Citations - 44864
René Adam is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 92, co-authored 578 publications receiving 37929 citations. Previous affiliations of René Adam include University of Padua & University of Paris.
Papers
More filters
Journal ArticleDOI
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
Edward K. Geissler,Andreas A. Schnitzbauer,Andreas A. Schnitzbauer,Carl Zülke,P. Lamby,Andrea Proneth,Christophe Duvoux,Patrizia Burra,Karl-Walter Jauch,Markus Rentsch,Tom M. Ganten,Jan Schmidt,Utz Settmacher,Michael Heise,Michael Heise,Giorgio Rossi,Umberto Cillo,Norman M. Kneteman,René Adam,Bart van Hoek,Philippe Bachellier,Philippe Wolf,Lionel Rostaing,Wolf O. Bechstein,Magnus Rizell,James J. Powell,Ernest Hidalgo,J. Gugenheim,Heiner Wolters,Jens Brockmann,André Roy,Ingrid Mutzbauer,Angela Schlitt,Susanne Beckebaum,Christian Graeb,Silvio Nadalin,Umberto Valente,Victor Sanchez Turrion,Neville V. Jamieson,T. Scholz,Michele Colledan,Fred Fändrich,Thomas Becker,Gunnar Söderdahl,Olivier Chazouillères,Heikki Mäkisalo,Georges-Philippe Pageaux,Rudolf Steininger,Thomas Soliman,Koert P. de Jong,Jacques Pirenne,Raimund Margreiter,Johann Pratschke,Antonio Daniele Pinna,Johann Hauss,Stefan Schreiber,Simone I. Strasser,Jürgen Klempnauer,Roberto Troisi,Sherrie Bhoori,Jan Lerut,Itxarone Bilbao,Christian Klein,Alfred Königsrainer,Darius F. Mirza,Gerd Otto,Vincenzo Mazzaferro,Peter Neuhaus,Hans J. Schlitt +68 more
TL;DR: This trial provides the first high-level evidence base for selecting immunosuppression in LTx recipients with HCC and reveals that low-risk, rather than high- risk, patients benefited most from sirolimus; furthermore, younger recipients (age ⩽60) also benefited, as well siro Limus monotherapy patients.
Journal ArticleDOI
Is liver resection justified for patients with hepatic metastases from breast cancer
René Adam,Thomas A. Aloia,Jinane Krissat,Marie Pierre Bralet,Bernard Paule,Sylvie Giacchetti,Valérie Delvart,Daniel Azoulay,Henri Bismuth,Denis Castaing +9 more
TL;DR: In this paper, the authors examined their experience with hepatic resection (HR) in a relatively unselected group of patients with breast cancer liver metastases (BCLM), and concluded that HR is safe and may provide a significant survival benefit over medical therapy alone.
Journal ArticleDOI
Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases
Dennis A. Wicherts,R.K. Miller,Robbert J. de Haas,Georgia Bitsakou,Eric Vibert,Luc-Antoine Veilhan,Daniel Azoulay,Henri Bismuth,Denis Castaing,René Adam +9 more
TL;DR: Two-stage hepatectomy provides a 5-year survival of 42% and a hope of long-term survival for selected patients with extensive bilobar CLM, irresectable by any other means.
Journal ArticleDOI
Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience.
Henri Bismuth,Didier Samuel,Denis Castaing,René Adam,Faouzi Saliba,Marc Johann,Daniel Azoulay,Béatrice Ducot,Laurence Chiche +8 more
TL;DR: Orthotopic liver transplantation is an effective treatment in fulminant hepatitis and use of high-risk grafts permitted transplantation of 83% of patients, but was responsible for higher mortality.
Journal ArticleDOI
Complete Pathologic Response After Preoperative Chemotherapy for Colorectal Liver Metastases: Myth or Reality?
René Adam,Dennis A. Wicherts,Robbert J. de Haas,Thomas A. Aloia,Francis Lévi,Bernard Paule,Catherine Guettier,Francis Kunstlinger,V. Delvart,Daniel Azoulay,D. Castaing +10 more
TL;DR: CPR was observed in 4% of patients with CLM treated with preoperative chemotherapy, however, CPR may occur in almost one-third of objective responders age